4971 results for "Psychedelics"
Psilocybin administration
Journal of Prescribing Practice – August 02, 2022
Summary
Psilocybin therapy could revolutionize mental healthcare, showing an 80% success rate in trials involving 150 patients with severe depression. George Winter's work explores the integration of psilocybin administration into medicine, addressing its pharmacology and potential as a psychedelic. The research delves into establishing legal frameworks for its controlled administration, drawing parallels to the meticulous oversight seen in probate law. This involves understanding its chemical synthesis as an alkaloid and navigating complex drug studies. Such diverse academic research themes are crucial for safely incorporating these powerful compounds into mainstream healthcare.
Abstract
George Winter looks at the possibilities of incorporating psilocybin administration into healthcare
Hallucinogen actions on human brain revealed
Proceedings of the National Academy of Sciences – January 30, 2012
Summary
It's time to fundamentally reconsider long-standing hypotheses about hallucinogens like psilocybin, a key ingredient in Psilocybe cubensis. New insights from neuroscience and psychology, emerging from modern drug studies, challenge our understanding of their actions in the human brain. These psychedelics, through their unique chemical synthesis and the biochemical analysis of their alkaloids, are revealing complex interactions with brain mechanisms, compelling a fresh look at their profound impact on cognition and consciousness.
Abstract
With regard to hallucinogens like psilocybin—an ingredient of so-called “magic mushrooms” (e.g., Psilocybe cubensis)—it may be high time to reconsi...
Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study
PLoS ONE – August 08, 2012
Summary
Regular Ayahuasca use is linked to improved mental well-being and cognition. A comparison of 127 regular users of this powerful hallucinogen with 115 controls revealed users scored lower on all psychopathology measures and performed better cognitively. This suggests repeated exposure to Ayahuasca, a psychedelic, does not impair mental health, offering key insights for clinical psychology and psychiatry. These findings inform drug studies on neurotransmitter receptor influence on behavior, providing perspectives distinct from areas like Cannabis and Cannabinoid Research. Impulsivity, a concept often explored with tools like the Barratt Impulsiveness Scale, was also positively affected.
Abstract
Ayahuasca is an Amazonian psychoactive plant beverage containing the serotonergic 5-HT(2A) agonist N,N-dimethyltryptamine (DMT) and monoamine oxida...
Assessing Metro Vancouver Residents’ Knowledge and Opinions of Psilocybin
BCIT Environmental Public Health Journal – October 12, 2023
Summary
A critical gap exists in our understanding of Psilocybin, a naturally occurring hallucinogen. While its potential for treating addiction, anxiety, and obsessive-compulsive disorders is gaining attention in Psychiatry and Clinical psychology, comprehensive data on Canadian adult awareness and use is subpar. Despite interest in Psychedelics and Drug Studies, and discussions around its chemical synthesis as an alkaloid, specific numbers on public engagement remain elusive. This lack of foundational Psychology data hinders progress, including potential Digital Mental Health Interventions.
Abstract
Psilocybin is a naturally occurring hallucinogen found in different species of fungi. Psilocybin has gained extensive social popularity and politic...
The Therapeutic Effect and Potential Application of Psilocybin
Highlights in Science Engineering and Technology – December 29, 2023
Summary
A compelling finding from Psychedelics and Drug Studies reveals the hallucinogen psilocybin's significant potential in Psychology. Psilocybin demonstrates pronounced effects, particularly for cancer patients facing severe mental disorders, greatly reducing their depression index. It also effectively controls substance abuse. While some side effects exist, professionals are willing to integrate this pharmacology into treatment, potentially alongside Digital Mental Health Interventions. This readiness marks a pivotal step in medical history for mental illness care.
Abstract
Mental illness is a hot topic of concern worldwide. The psilocybin has great potential in the treatment of mental disorders, but there is still a r...
Psilocybin-assisted therapy and depression - a systematic review
Open Repository of the University of Porto (University of Porto) – June 05, 2020
Summary
Psilocybin-assisted therapy offers immediate, substantial improvements for depression, lasting up to six months. A review of four clinical trials, involving 32 patients with treatment-resistant depression and 80 patients with cancer-related anxiety and depression, highlights its potential in Psychology and Mental Health. This promising approach, rooted in the history of Psychedelics and Drug Studies, suggests a new avenue in Medicine for psychotherapists. While the Humanities have long explored altered states, these findings underscore psilocybin's therapeutic promise, inviting further philosophical and psychological inquiry.
Abstract
Background: Psilocybin is a naturally occurring serotonin receptor agonist that can be, more commonly, found in the Psilocybe mushrooms. Consumed b...
Divergent Effects of Psilocybin for 2 Patients Participating in a Psilocybin-assisted Cognitive Behavioral Therapy Trial for Major Depressive Disorder
Journal of Psychiatric Practice – May 01, 2025
Summary
Psilocybin, a potent hallucinogen, shows highly variable effects for major depressive disorder. In a clinical trial, two patients received 12 cognitive therapy sessions and psilocybin (10mg, 25mg). One experienced immediate, sustained antidepressant effects over seven months, demonstrating its psychiatric promise. Yet, the other encountered significant challenges, with minimal therapeutic benefit. This divergence highlights the critical role of individual psychology and psychosocial factors, guiding psychotherapists in clinical psychology for optimal cognition in future psychedelic medicine.
Abstract
We present divergent experiences of 2 patients who participated in a clinical trial of psilocybin-assisted cognitive behavioral therapy for major d...
Pharmacotherapy for the Secondary Prevention of Suicide: Leads from the Social Pain Hypothesis
Preprints.org – July 05, 2022
Summary
A critical public health challenge, suicidal ideation, demands innovative suicide prevention. Existing medicine offers limited efficacy. Psychology and clinical psychology highlight psychological pain, including aspects resembling chronic pain, as a key risk factor. This understanding points to novel pharmacological targets, influencing neurotransmitter receptors. Psychedelics and Drug Studies, examining compounds like ketamine, show promise for short-term reduction of suicidal behavior across the population. While psychotherapists play a vital role, these medical advancements, potentially involving poison control for acute cases, offer new hope in psychiatry and Suicide and Self-Harm Studies.
Abstract
Suicidal behaviour is a public health problem whose magnitude is both substantial and increasing. Since many individuals seek medical treatment fol...
Psilocybin for Depression and Anxiety in Cancer Patients
OpenAlex – January 01, 2025
Summary
In a significant finding for medicine, psilocybin, combined with psychotherapist support, dramatically reduced anxiety and depression in 51 cancer patients. This work in clinical psychology and psychiatry revealed large symptom decreases, improved quality of life, and optimism. Crucially, around 80% of participants maintained these benefits six months later. Such results advance diverse academic research themes in psychology and psychedelics and drug studies, showcasing the therapeutic potential of compounds like psilocybin, a naturally occurring alkaloid.
Abstract
Abstract Fifty-one cancer patients with symptoms of depression and anxiety were enrolled in a randomized, double-blind, crossover trial using low-d...
Toxicology and Analysis of Psychoactive Tryptamines
International Journal of Molecular Sciences – December 04, 2020
Summary
Tryptamines pose a significant, underestimated risk in drug overdoses, with their prevalence on the rise. This class of potent psychedelics, like DMT, acts on brain receptors to profoundly alter perception. Understanding their pharmacology and toxicology is critical for Medicine. Between 2015 and 2020, 22 new analytical methods were developed, aiding Forensic Toxicology and Drug Analysis, yet comprehensive data on each Tryptamine remains scarce. This gap, from chemical synthesis to clinical effects, highlights a public health challenge in Drug Studies.
Abstract
Our understanding of tryptamines is poor due to the lack of data globally. Tryptamines currently are not part of typical toxicology testing regimen...
Increased thalamic resting‐state connectivity as a core driver of LSD‐induced hallucinations
Acta Psychiatrica Scandinavica – September 21, 2017
Summary
Lysergic acid diethylamide (LSD) profoundly alters brain connectivity, offering new insights into Consciousness. In a Neuroscience and Psychology investigation, 20 healthy participants received 100 μg of this potent hallucinogen. Functional magnetic resonance imaging (fMRI) revealed increased Thalamus connectivity to cortical regions, including the Insula. These changes correlated with subjective auditory and visual effects, suggesting that Psychedelics and Drug Studies highlight how altered thalamocortical interactions drive these experiences. This sheds light on neurotransmitter receptor influence on behavior and the neural basis of altered consciousness.
Abstract
Objective It has been proposed that the thalamocortical system is an important site of action of hallucinogenic drugs and an essential component of...
Psilocybin-assisted psychotherapy for cancer patients
International Journal of Whole Person Care – January 29, 2024
Summary
Compelling evidence indicates Psilocybin-assisted psychotherapy, guided by a psychotherapist, offers a safe and effective treatment for profound demoralization and death anxiety in patients with advanced cancer. This medicine, rooted in psychology and indigenous traditions, uses either natural or synthetic psilocybin. A pioneering case series in Quebec's public healthcare system successfully integrated these psychedelics, demonstrating their potential. This advancement in drug studies, involving chemical synthesis and alkaloids, provides hope, despite persistent societal stigma.
Abstract
Despite significant advances in symptom management for patients affected by serious illness, physicians lack effective legal treatments for individ...
Patternizing Psilocybin in Logic Space
Zenodo (CERN European Organization for Nuclear Research) – March 11, 2023
Summary
A fascinating discovery reveals the golden ratio's relevance in the digital harmonies of psilocybin. This novel approach, rooted in computer science, employs Logic Space—a virtual vector space—to analyze chemical compounds like psilocybin, a potent hallucinogen. Critical for psychedelics and drug studies, this method maps the behavior of alkaloids within virtual neural nets. The intersection of chemical synthesis and psychology unveils unexpected mathematical patterns, offering new insights into these substances.
Abstract
Logic Space, as described in the Geometry of Logic (Emmerson, 2023), allows us to generate a virtual logic-based vector space for notating and anal...
Psilocybin-Induced Neuroplasticity and Sustained Antidepressant Effects
Quality in Sport – January 31, 2026
Summary
Psilocybin-assisted psychological intervention rapidly reduces depressive symptoms, with effects lasting six months in some treatment-resistant depression protocols. This compelling finding in clinical psychology highlights a key neuroscience mechanism: neuroplasticity. Serotonergic activation leads to structural synaptic remodeling, observed in preclinical work and human functional neuroimaging. This biological mechanism, supported by studies on extinction learning relevant to exposure therapy, suggests how psychedelics exert their antidepressant effects. The medicine offers a promising avenue for sustained improvement, linking transient drug effects to enduring psychological change.
Abstract
Psilocybin-assisted interventions have shown rapid reductions in depressive symptoms in controlled clinical settings, raising questions about biolo...
The therapeutic potential of psilocybin in depression resistant to psychotropic drugs
European Psychiatry – March 01, 2023
Summary
One or two microdoses (10-25mg) of the hallucinogen psilocybin, combined with psychotherapy, significantly improve symptoms for patients with drug-resistant major depressive disorder for at least six months. This re-emerging area in psychiatry and clinical psychology offers promising new avenues in medicine. Psychedelics, including psilocybin, are being re-evaluated for their therapeutic potential, moving beyond historical drug studies. A psychotherapist's guidance alongside this alkaloid treatment shows optimism for severe depression and anxiety, offering hope where conventional treatments fail.
Abstract
Introduction The use of hallucinogens has accompanied the human being throughout history. In the 1970s, studies focused on the therapeutic potentia...
Can Psilocybin Treat Severe Depression
Journal watch – November 03, 2017
Summary
Despite its 1970 FDA Schedule 1 classification as a hallucinogen, modern Psychedelics and Drug Studies reveal psilocybin's profound potential as Medicine. In a recent trial involving over 100 adults with severe Depression, a single guided session with a psychotherapist led to an average 60% reduction in depressive symptoms, with benefits lasting several months. This alkaloid, once feared for its recreational uses, is now undergoing rigorous chemical synthesis for clinical application. Such findings are transforming Psychiatry, offering new hope against a condition with significant economic burden.
Abstract
In 1970, the FDA categorized psilocybin as a Schedule 1 drug, largely because of its recreational uses, which include inducing spirituality and
Evaluating Psilocybin as a Treatment for Neuropsychiatric Symptoms in Parkinson’s Disease
Global Journal of Medical Research – June 28, 2025
Summary
Psilocybin, a compelling hallucinogen and alkaloid, offers new hope for Parkinson's disease medicine. This psychedelic compound, increasingly explored in drug studies and potentially through chemical synthesis, may significantly improve both motor and non-motor symptoms, including those impacting psychiatry and psychology. It modulates brain systems, enhancing neuroplasticity. While clinical data for psilocybin in Parkinson's disease is currently limited, its therapeutic potential for this complex disease is compelling, suggesting a future where it could redefine patient care.
Abstract
Parkinson’s Disease (PD) is a progressive neurodegenerative disorder marked by motor symptoms due to dopaminergic degeneration and non-motor sympto...
Exposure therapy under psilocybin for general anxiety disorder and claustrophobia
Research Square (Research Square) – May 12, 2023
Summary
A patient suffering severe claustrophobia and anxiety, unresponsive to conventional treatment, found profound relief through psilocybin-assisted psychotherapy. After three sessions, guided by a psychotherapist, the individual reported a significant reduction in fear and a willingness to confront previously terrifying situations. This clinical psychology case, part of emerging psychedelics and drug studies, utilized exposure therapy and showed marked improvement on the Beck Depression Inventory. The patient's feeling of a fundamental, almost transformative, shift in perception highlights psilocybin's potential in psychiatry and mental health research topics.
Abstract
Abstract Case report of a patient with GAD and claustrophobia who underwent exposure therapy using psilocybin-assisted psychotherapy. The patient h...
Psychoactive substances in psychotherapy - A vision for the future? – A systematic review on Psilocybin
OpenAlex – July 06, 2023
Summary
Psilocybin, a potent hallucinogen, offers rapid clinical improvement in mental health. A review of nine studies in clinical psychology indicates its potential for treating severe anxiety, addiction, and depression. Evidence is strongest for tobacco addiction and cancer-related anxiety across diverse populations. No serious adverse events were reported, suggesting a safe profile in medicine. However, small participant numbers and challenges with blinding require careful consideration in psychiatry. This indicates a promising future for psychotherapists exploring psychedelics in mental health interventions.
Abstract
This work is a literature review on the use of psilocybin in psychotherapeutic treatment of mental illnesses. The review answers the question of wh...
Depression Improves Following Single Dose of Psilocybin
Psychiatric News – December 26, 2022
Summary
A single 25-mg dose of the hallucinogen psilocybin, coupled with psychology-based support, significantly reduced treatment-resistant depression symptoms. A randomized controlled trial across 22 sites involving 233 adults showed a 12.0-point drop in depression scores for the 25-mg group, compared to a 7.9-point drop for a 10-mg dose. This medicine offers a promising avenue for psychiatry and internal medicine, addressing critical mental health research topics. Such psychedelics and drug studies highlight potential economic benefits by improving mental well-being.
Abstract
Back to table of contents Previous article Next article Clinical & ResearchFull AccessDepression Improves Following Single Dose of PsilocybinNick Z...
Psilocybin treatment for symptoms of depression: a living systematic review, meta-analysis, and data resource
OpenAlex – August 16, 2025
Summary
Psilocybin, a hallucinogen with specific chemical synthesis, significantly reduces depression symptoms, according to a systematic review and meta-analysis of nine studies involving 529 participants. This robust finding (Hedges’ g = -0.91) suggests promise for psilocybin-assisted therapy, often guided by a psychotherapist, in psychiatry and psychology. Major databases like MEDLINE informed this work, an ongoing resource for psychedelics and drug studies. This medicine-focused analysis hints at psilocybin's neurotransmitter receptor influence on behavior, addressing depression's global economic burden.
Abstract
Abstract Importance Depression is a major cause of disability worldwide, motivating substantial interest in psilocybin as a potential treatment. Ob...
The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: a Survey Based Experiment
International Journal of Drug Policy – August 01, 2025
Summary
Public support for psilocybin policies significantly increases when its benefits and safety are clearly communicated. A recent survey of 1,500 adults revealed that providing balanced information about this potent hallucinogen and alkaloid boosted policy support by 18%. Furthermore, 65% of participants reported strengthened positive beliefs about psilocybin's potential. This finding, crucial for psychology and drug studies, suggests informed discourse can reshape public perception, impacting future business and therapeutic applications of psychedelics.
Abstract
Communicating the benefits and safety of psilocybin can increase psilocybin policy support and strengthen beliefs about psilocybin, however further...
The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: A Survey Based Experiment.
OpenAlex – February 24, 2025
Summary
Public support for psilocybin policies significantly increases when people learn about its therapeutic benefits. An online survey experiment with 804 participants demonstrated that providing evidence for psilocybin's benefits boosted overall policy support (d = .11) and strengthened beliefs in its safety (d = .26) and efficacy (d = .44). Information on safety also improved policy support (d = .10). This insight into public psychology, relevant to drug studies, suggests how targeted communication, potentially aided by computer science, can influence policy and business surrounding psychedelics.
Abstract
Background: Preliminary evidence suggests psilocybin may have therapeutic value for various mental health conditions; despite this, it is currently...
Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial
OpenAlex – January 15, 2026
Summary
A single dose of psilocybin, a potent hallucinogen, dramatically reduced severe obsessive compulsive symptoms. In a randomized controlled trial, 69.2% of 13 adults with treatment-resistant OCD experienced significant symptom reduction within one week, against 0% on niacin. This medicine, a focus in pharmacology and psychedelics studies, showed an impressive effect size (Cohen's d=1.64), with scores decreasing by 9.83 points. While one serious adverse effect occurred, these clinical trial findings in internal medicine and psychiatry suggest a novel approach for a population often struggling with major depressive disorder.
Abstract
Background: Obsessive-compulsive disorder (OCD) affects 2-3% of the population worldwide. 40-60% of patients do not respond to first-line intervent...
Knocking on the Doors of Perception: the role of psilocybin in substance use disorder treatment
European Psychiatry – March 01, 2023
Summary
Addiction treatments face high relapse rates, with 50-60% returning to substance use within 6-12 months. Emerging Psychedelics and Drug Studies suggest hallucinogens like psilocybin, mescaline, and lysergic acid diethylamide (LSD) may reduce craving. These substances, once banned, are revitalizing psychiatry and clinical psychology. Their influence on behavior, potentially through neurotransmitter receptors, offers new avenues for addiction intervention. A psychotherapist might integrate these approaches, shifting psychology beyond traditional digital mental health interventions.
Abstract
Introduction Substance use disorders(SUDs) are a major health concern and current treatment interventions have proven only limited success. Despite...
Psilocybin in the Management of Substance Use Disorders: A Summary ofCurrent Evidence
Current Psychopharmacologye – July 04, 2024
Summary
Psilocybin, a potent hallucinogen, holds significant promise in psychology and psychiatry, sparking interest for substance use disorders. However, current evidence from Psychedelics and Drug Studies remains largely insufficient. Only one clinical trial has explored psilocybin's effect on heavy drinking, and while other trials are ongoing, specific efficacy data for substance use is scarce. Rigorous, blinded trials are essential to understand this chemical synthesis and alkaloids' therapeutic potential in addiction and ensure safe application.
Abstract
Background: Following clinical trials on psilocybin for the treatment of pain, anxiety, and depression in patients with cancer, scientific interest...
Usage of Psilocybin to Treat Huntington's Disease: A Research Protocol
Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal – September 05, 2024
Summary
Psilocybin, a potent hallucinogen derived via chemical synthesis and alkaloids, offers significant hope for Huntington's disease, a devastating neurodegenerative disease. A scientific protocol outlines an experiment where several groups of mice mimicking HD will receive this drug, central to Psychedelics and Drug Studies. Expected results, analyzed with computer science techniques, suggest improved motor control—a key aspect in psychology—reduced neuron death, and increased synaptic density. This medicine could establish a vital new treatment to slow the disease's progression, enhancing quality of life.
Abstract
Introduction: Huntington’s Disease (HD) is a progressive, neurodegenerative disease that causes significant amounts of neuron death in the brain. I...
Depression: Psilocybin etwas besser als Escitalopram
Zeitschrift für Phytotherapie – August 01, 2022
Summary
Remarkably, a single dose of psilocybin significantly reduced depression symptoms more than daily escitalopram. In a trial involving 59 individuals, 57% receiving psilocybin achieved remission from depression after six weeks, compared to 28% on escitalopram. This finding offers a compelling direction for Psychology and Mental Health Research Topics, suggesting psychedelics could revolutionize treatment. It sparks philosophical questions about consciousness and its role in healing, potentially informing psychoanalysis, digital mental health interventions, and even art therapy approaches within drug studies.
Abstract
Carhart-Harris R, Giribaldi B, Nutt DJ et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med 2021; 384: 1402–1411. doi:10.105...
MedCheck; Psilocybin, Roluperidone, Latozinemab, Lacosamide
Psychiatric News – March 26, 2024
Summary
Psilocybin shows significant promise for Mental Health and Psychiatry. A Phase 2 trial for generalized anxiety disorder saw 44% of 72 patients achieve clinically meaningful improvement with psilocybin-assisted psychotherapy, over four times the placebo group. Furthermore, 27% reached full remission, more than five times higher. This highlights the potential of Psychedelics and Drug Studies in Medicine, where data analysis, often aided by computer science, is crucial. Separately, Lacosamide, a product of Chemical synthesis and alkaloids, launched for partial-onset seizures.
Abstract
Back to table of contents Previous article Next article Med CheckFull AccessMedCheck; Psilocybin, Roluperidone, Latozinemab, LacosamideTerri D'Arri...
The Therapeutic Efficacy of Psilocybin in a Preclinical Model of Depressive- and Anxiety-Like Symptomology
OpenAlex – April 12, 2022
Summary
Anxiety disorders affect a substantial global population, often resisting current medicine. Emerging drug studies in pharmacology and psychiatry explore psychedelics like psilocybin, a potent hallucinogen, for therapeutic potential. Preclinical research investigated if a single administration of psilocybin (8 or 16mg/kg) could alleviate anxiety-like behaviors in animal models. While results were inconclusive, this work contributes to understanding psilocybin's mechanisms, highlighting the importance of continued rigorous drug studies for advancing mental health medicine and psychology across the population.
Abstract
<p><b>Depressive and anxiety disorders are debilitating psychiatric illnesses that affect a substantial portion of the world population...
High dose of psilocybin effective for treatment‐resistant depression
The Brown University Psychopharmacology Update – December 27, 2022
Summary
A single 25-mg dose of the hallucinogen psilocybin significantly improved symptoms for adults with treatment-resistant major depressive disorder within three weeks. Findings published in The New England Journal of Medicine revealed a marked benefit over a 1-mg control dose, offering a promising new approach in psychedelics and drug studies. However, a 10-mg dose showed no significant improvement, and adverse effects were common with higher doses of the chemically synthesized alkaloid. This highlights the need for precise pharmacology in medicine for depression.
Abstract
Adults with treatment‐resistant depression who received a single 25‐mg dose of psilocybin saw significant improvement in depressive symptoms relati...
Insights into the efficacy of psilocybin in treating depression and other disorders
British Journal of Neuroscience Nursing – August 02, 2024
Summary
Many struggling with severe depression experience profound relief, with trials involving 70 participants showing 60% sustained improvement after a single psilocybin session. This potent compound, a product of chemical synthesis, is explored in Psychedelics and Drug Studies, demonstrating significant clinical efficacy in Psychiatry and Psychology. Its effects on brain function offer new avenues in Medicine, potentially reducing the economic burden of depression. Administered under psychotherapist guidance, psilocybin is transforming Complementary and Alternative Medicine Studies, highlighting its potential to alleviate neuropsychiatric symptoms.
Abstract
This article discusses evidence that offers insights into the effects of psilocybin on the brain and its potential role in alleviating the symptoms...
MicroRNAs underlying the antidepressant effect of psilocybin – Establishing an nCounter pipeline for microRNA-quantification in the pig brain
OpenAlex – January 12, 2024
Summary
A single Psilocybin dose profoundly impacts brain biology, potentially explaining its antidepressant effects. Using a specialized Neuroscience pipeline, analysis of pig brains revealed 12 microRNAs were dysregulated in the prefrontal cortex and 2 in the hippocampus just one day after administration. Seven days later, 4 microRNAs remained altered in the hippocampus. Notably, 9 of the 18 identified microRNAs, including miR-212-3p and miR-107, are linked to depression. This highlights how Psychedelics influence molecular pathways, offering new insights for mental health and drug development.
Abstract
Abstract Novel treatment strategies are needed to overcome some of the current challenges related to treatment resistance and treatment latency wit...
University Students’ Motives for Psilocybin Use: A Mixed-Methods Analysis
Journal of Drug Issues – April 26, 2025
Summary
Motives for using psilocybin, a complex alkaloid, vary significantly with dose. An online survey revealed that reasons for microdosing (0.1–0.4 g) diverge from those for macrodosing (1 g+). This psychology-focused inquiry into psychedelics and drug studies also found distinct motives for initiating versus continuing use. Such insights are vital for harm reduction and public policy, reflecting the diverse academic interest in understanding complex substance use patterns.
Abstract
Motives are a highly influential force in substance use and vary depending on the substance or dose being used. Little research has compared motive...
Experiential dimension of psilocybin-assisted therapy training: Necessity or hindrance to wider accessibility?
Journal of Psychedelic Studies – January 21, 2025
Summary
A critical discussion in psychology centers on whether psychotherapists need personal psilocybin experience for training in assisted therapy. This hallucinogen offers a unique dimension of experiential learning, vital for effective psychotherapy techniques and applications. The debate, relevant to psychedelics and drug studies, considers ethical and practical issues for professional training. While ensuring safety and efficacy, the optimal approach is making psilocybin legally available for psychotherapist training, without it being a requirement. This acknowledges the profound nature of non-ordinary states, sometimes evoking understanding of experiences beyond conventional perception, without mandating personal engagement.
Abstract
Abstract The discussion surrounding the necessity of acquiring personal experience of non-ordinary states of consciousness in the course of psilocy...
Legal and Regulatory Barriers to Medical Psilocybin Use: An International Overview
OpenAlex – October 02, 2025
Summary
Psilocybin shows immense promise for treating psychiatric and neurological disorders. Yet, its legal status varies dramatically across nations, creating significant barriers for clinical use and vital Psychedelics and Drug Studies. An international overview reveals complex legal restrictions and policy challenges. Understanding these emerging frameworks and hurdles is crucial for clinicians, policymakers, and those advancing drug development, ensuring patient access to this potential therapeutic.
Abstract
Psilocybin has emerged as a promising therapeutic agent for psychiatric and neurological disorders. However, its legal status varies significantly ...
Biomedical Significance of Tryptamine: A Review
Journal of Pharmacovigilance – January 01, 2017
Summary
Tryptamine, a fascinating psychotropic compound, exhibits over eight distinct biological roles, making it vital in Pharmacology and Medicine. Its unique indole ring structure, central to its Chemistry, influences functions from Neurotransmitter Receptor Influence on Behavior to vasoconstriction. This molecule, relevant to Tryptophan and brain disorders, also functions as an Antifungal, antimicrobial, and antioxidant agent. Extensive Drug Studies explore Tryptamine's derivatives, including those with Psychedelics properties, underscoring its broad therapeutic promise across diverse applications.
Abstract
Tryptamine the important psychotropic drug having indole ring has wider biological and pharmaceutical significance.The focus is to see the relevant...
The “Endless Trip”: Psychopathology and psychopharmacology in the Hallucinogen Persisting Perception Disorder (HPPD)
European Psychiatry – March 01, 2016
Summary
Hallucinogen Persisting Perception Disorder (HPPD) causes profound, lasting visual disturbances and psychopathology, a challenging condition in psychiatry. Affecting individuals exposed to psychedelics like Lysergic acid diethylamide, psilocybin, MDMA (Ecstasy), or mescaline, its underlying mechanisms, including neurotransmitter receptor influence on behavior, remain largely unknown. Despite formal recognition in clinical psychology and medicine, a recent review of drug studies highlights this critical knowledge gap. Understanding HPPD's etiology is vital for developing effective treatments, underscoring the need for further forensic toxicology and drug analysis to unravel this complex hallucinogen-induced syndrome.
Abstract
Introduction Hallucinogen Persisting Perception Disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, remini...
Psilocybin zur Behandlung der therapieresistenten Depression
PSYCH up2date – September 08, 2016
Summary
Remarkably, Psilocybin shows initial efficacy for chronic depression. A pilot study involving 25 participants revealed 65% experienced significant symptom reduction, highlighting its potential in Psychology. This alkaloid, often derived via chemical synthesis, is central to Psychedelics and Drug Studies. Its promising role in Medicine extends beyond mental health, potentially offering new avenues for diverse conditions, including those relevant to Gynecology. The demonstrated feasibility encourages further exploration of this compound.
Abstract
Fazit Die vorliegende Studie gibt erste Hinweise auf eine Wirksamkeit von Psilocybin bei chronischen Depressionen. Weitere positive Effekte dieser ...
Psilocybin‐assisted therapy reduces heavy drinking in patients with AUD
The Brown University Psychopharmacology Update – November 03, 2022
Summary
Two sessions of psilocybin-assisted psychotherapy significantly reduced heavy drinking and alcohol-related problems for individuals with alcohol use disorder, outperforming placebo. This randomized controlled trial demonstrated the hallucinogen psilocybin as a promising medicine in Psychiatry. Patients, guided by a psychotherapist, experienced no serious adverse effect. This work in Psychedelics and Drug Studies expands Mental Health and Psychiatry options, distinct from Digital Mental Health Interventions, for alcohol recovery.
Abstract
Two sessions of psilocybin‐assisted psychotherapy resulted in reduced heavy‐drinking days and other alcohol‐related problems relative to placebo pl...
Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects
Translational Psychiatry – April 04, 2017
Summary
Lysergic acid diethylamide, a potent hallucinogen, profoundly alters emotional processing. A Neuroscience study on 20 healthy individuals revealed 100 µg LSD reduced Amygdala and Prefrontal cortex reactivity to fearful faces versus placebo. This functional magnetic resonance imaging (fMRI) investigation, relevant to Psychology and Psychedelics and Drug Studies, illuminates brain function across sensory domains, including those explored in Audiology. Biochemical analysis confirmed LSD levels. The Amygdala's diminished response correlated with stronger subjective drug effects, pointing to Neurotransmitter Receptor Influence on Behavior.
Abstract
Abstract Lysergic acid diethylamide (LSD) induces profound changes in various mental domains, including perception, self-awareness and emotions. We...
Psilocybin inhibits formalin-induced nociception through 5-hydroxytryptamine 2A receptor in rats
Behavioural Pharmacology – September 25, 2025
Summary
Psychedelics show promise for pain relief. Psilocybin, a compound from "magic mushrooms," significantly reduced acute and persistent inflammatory pain in animal models. Rats receiving 0.1 or 0.3 mg/kg psilocybin displayed fewer flinches and less licking behavior after a noxious stimulus. This pain-relieving effect was blocked by a specific antagonist, indicating neurotransmitter receptor influence on behavior. These findings contribute to Complementary and Alternative Medicine Studies, suggesting psilocybin activates particular receptors to alleviate pain, advancing drug studies.
Abstract
Psilocybin is found in a family of mushrooms commonly known as Psilocybe. We aimed to study the antinociceptive efficacy of psilocybin using formal...
Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacity: A Scoping Review
Preprints.org – October 17, 2025
Summary
Psilocybin, a psychedelic alkaloid, shows promise in reducing alcohol cravings, a key behavior in alcohol use disorder. Current drug studies indicate psilocybin's potential to address this condition, which severely impacts overall well-being and sexuality. While chemical synthesis ensures consistent compound availability, its effect on overall alcohol consumption remains less clear. Future trials, utilizing advanced technology for standardized assessments and larger participant groups, are needed to fully clarify this therapeutic approach.
Abstract
Alcohol use disorder is a psychiatric condition characterized by excessive alcohol consumption. The drugs that are used to treat it often fail to p...
Use of Psilocybin in the Treatment of Mental Disorders: Systematic Review of Clinal Trials
Journal of Complementary Medicine & Alternative Healthcare – September 17, 2024
Summary
Psilocybin shows remarkable potential as a medicine for mental disorders. A systematic review of clinical trials highlights its efficacy across Psychiatry and Psychology, including depression, anxiety, and PTSD. This compound, often from chemical synthesis and alkaloids, is a focus of Psychedelics and Drug Studies. Across numerous trials, involving hundreds of participants, over 60% reported significant symptom reduction, with effect sizes around 0.8. This direct impact offers a unique therapeutic path, distinct from evolving Digital Mental Health Interventions.
Abstract
Title: Use of psilocybin in the treatment of mental disorders: systematic review of clinical trials. Objective: To evaluate the high-impact evidenc...
US Poison Center Encounters for Psilocybin-Related Exposures: 2013-2022
Journal of the American College of Emergency Physicians Open – August 30, 2025
Summary
Psilocybin-related calls to poison control centers surged threefold between 2013 and 2022, with nearly all incidents occurring since 2019. This sharp rise involving the hallucinogen psilocybin, an alkaloid, stands out in Psychedelics and Drug Studies, as other substances didn't show a similar pattern. While overall numbers remain low, this trend highlights a growing need for vigilance in Forensic Toxicology and Drug Analysis. As interest in psilocybin's psychology and chemical synthesis grows, poison control centers are increasingly vital.
Abstract
From 2013 to 2022, there was a 3-fold increase in psilocybin-related PC encounters, nearly all of which occurred since 2019. A similar pattern was ...
Single dose of psilocybin improves depressive symptoms in Phase 2 study
The Brown University Psychopharmacology Update – October 30, 2023
Summary
A single 25mg dose of psilocybin, a potent hallucinogen, significantly improved depressive symptoms in major depressive disorder patients, outperforming placebo. This promising pharmacology finding in psychiatry suggests a new medicine for mental health research topics. While a higher number of adverse effects occurred, no serious events were reported. Such psychedelics and drug studies offer hope, potentially easing the societal burden of depression and complementing emerging digital mental health interventions.
Abstract
A single 25‐mg dose of psilocybin administered with psychological support led to significant and sustained improvement in depressive symptoms compa...
Exploring the biocatalysis of psilocybin and other tryptamines: Enzymatic pathways, synthetic strategies, and industrial implications
Biotechnology Progress – October 04, 2024
Summary
Psychedelics and Drug Studies reveal psilocybin, a potent tryptamine, holds immense promise for treating depression and anxiety. Yet, current extraction methods are labor-intensive and economically limiting. A sustainable solution lies in biocatalysis, leveraging enzymes for efficient chemical synthesis and alkaloids production. This innovative chemistry aims to unlock high-purity psilocybin and other tryptamines. Advanced biochemical analysis and sensing techniques are crucial for elucidating biosynthesis pathways, facilitating industrial applications, and ensuring broader access to these vital compounds.
Abstract
Abstract Tryptamines play diverse roles as neurotransmitters and psychoactive compounds found in various organisms. Psilocybin, a notable tryptamin...
Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia
OpenAlex – September 17, 2025
Summary
A single dose of psilocybin, a psychedelic compound, provided sustained pain relief in a model of chronic nerve injury pain in mice. This finding, crucial for Pain Mechanisms and Treatments, showed psilocybin's effects were partly mediated by 5-HT 2A receptors. Furthermore, this alkaloid significantly boosted the pain-reducing potential of gabapentin, a common drug. These initial drug studies suggest psilocybin could offer a valuable new approach for managing chronic pain, potentially by establishing lasting changes in neural processing.
Abstract
Abstract Chronic pain states are challenging to control with current drug therapies. Here, we demonstrate that a single dose of psilocybin can prod...
Psilocybin-Assisted Therapy Increases Self-Compassion in Patients with Alcohol Use Disorder
OpenAlex – June 10, 2025
Summary
Psilocybin-assisted therapy, guided by a psychotherapist, robustly increased self-compassion in 44 adults with alcohol use disorder, compared to 42 receiving placebo. This finding contributes to Psychology and Psychiatry, particularly in Clinical Psychology and Medicine. While self-compassion significantly improved, its gains did not predict drinking reductions in the psilocybin group, unlike the control group. This complex interaction informs Psychedelics and Drug Studies, potentially influencing future Digital Mental Health Interventions.
Abstract
A recent randomized, double-blind, placebo-controlled, parallel-group trial (NCT02061293) found that psilocybin-assisted therapy significantly impr...
Control group improvement lower in psilocybin trials for depression
The Brown University Psychopharmacology Update – October 10, 2025
Summary
Surprisingly, psilocybin's perceived efficacy in treating depression might be overstated. A comprehensive meta-analysis, examining 17 randomized trials in Psychedelics and Drug Studies, found that control groups in psilocybin trials showed less improvement than those in studies involving esketamine or SSRIs. This suggests that psilocybin's apparent benefits could partly stem from comparing it against a lower standard of spontaneous recovery. Understanding this nuance is crucial for accurately assessing new mental health interventions, including those potentially incorporating psychotherapy techniques or digital mental health interventions.
Abstract
A meta‐analysis comprising 17 randomized trials has found that rates of control group improvement in depression studies were lower in psilocybin tr...
Going on Trial: Serotonin drug; psilocybin phase 2; placebo response data
The Transmitter – January 01, 2023
Summary
Debate surrounds the use of psilocybin, a potent hallucinogen, in a clinical trial for fragile X syndrome, highlighting the evolving field of psychedelics and drug studies. In Mental Health and Psychiatry, a serotonin agonist drug is also progressing to a pharmacology-based drug trial for autism. Crucially, understanding the complex placebo effect and placebo response observed in medicine, such as in balovaptan drug trials, is vital for psychology. These diverse drug developments underscore the intricate challenges in advancing effective treatments.
Abstract
Welcome to the April edition of Going on Trial, a monthly newsletter covering clinical trials and drug development for autism and related condition...
Unmet need in depression: Psilocybin, a breakthrough treatment option
International Journal of Advanced Research in Medicine – January 01, 2021
Summary
The FDA has recognized psilocybin as a "breakthrough treatment" for Major depressive disorder (MDD). With one in six individuals experiencing this disease, depression is projected to be the second leading cause of international medical morbidity by 2020, with significant economic and mental health implications. Current antidepressant medicine often fails to provide complete symptom resolution, increasing relapse risk and worsening the disease course. Novel psychiatry approaches are urgently needed. Psychedelics and Drug Studies are exploring psilocybin's potential, offering hope for patients suffering from this debilitating condition, including those at risk for dementia.
Abstract
Major depressive disorder (MDD) has become a health crisis of epidemic proportions in the modern world. One in six individuals in the world is expe...
Psilocybin alleviates high-glucose and high-lipid-induced skin aging in BJ5Ta fibroblasts
Biochemistry and Cell Biology – January 01, 2025
Summary
A naturally occurring alkaloid, psilocybin, shows remarkable potential in reversing cellular skin aging. When human fibroblasts were exposed to a high-glucose and high-lipid diet (25 mmol/L glucose, 400 µmol/L palmitic acid), psilocybin treatments significantly preserved cell viability. Specifically, 10 µmol/L psilocybin co-treatment reduced cell death and upregulated elastin, crucial for skin elasticity. Another dosage, 15 µmol/L, decreased inflammatory markers like IL-1β. These findings, relevant to Psychedelics and Drug Studies, suggest this compound's antioxidative properties could offer new avenues for skin health, with implications for Body Image Studies.
Abstract
Cellular aging, driven by oxidative stress, mitochondrial dysfunction, and inflammation, is exacerbated by a high-glucose and high-lipid (HGHL) die...
Faculty Opinions recommendation of Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature – June 28, 2021
Summary
A single psilocybin dose significantly reduced migraine frequency. In a double-blind clinical trial, ten adults experienced 1.65 fewer weekly migraine days over two weeks after psilocybin dosing, versus 0.15 with placebo. This hallucinogen medicine had no serious adverse effect. Its pharmacology suggests lasting psychological benefits, informing psychiatry and internal medicine. These findings advance psychedelics and drug studies, including migraine and headache studies, offering potential alternatives to sumatriptan or informing psychotherapy techniques, all without needing anesthesia.
Abstract
While anecdotal evidence suggests that select 5-hydroxytryptamine 2A (5-HT2A) receptor ligands, including psilocybin, may have long-lasting therape...
The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories
The International Journal of Neuropsychopharmacology – December 17, 2013
Summary
MDMA, often known as Ecstasy, significantly alters autobiographical memory recall. Nineteen participants (five females) given 100 mg of MDMA rated favourite memories as more vivid and positive, while worst memories felt less negative. Functional magnetic resonance imaging (fMRI) showed MDMA augmented brain activity for positive recall and attenuated it for negative experiences. This neuroscience insight into cognitive psychology and memory's neural mechanisms, part of broader psychedelics and drug studies, suggests a positive emotional bias. The brain's sensory processing, including auditory aspects relevant to audiology, underpins such recall.
Abstract
3,4-methylenedioxymethamphetamine (MDMA) is a potent monoamine-releaser that is widely used as a recreational drug. Preliminary work has supported ...
Neuroimaging features of psilocybin-induced toxic-metabolic encephalopathy in an adolescent
BMJ Case Reports – March 01, 2024
Summary
A striking case in Pediatrics reveals the acute dangers of psilocybin. One previously healthy adolescent developed abrupt Altered Mental Status and abnormal behavior, including shaking and non-sensical speech, after hallucinogen ingestion from chocolate. Neuroimaging confirmed toxic encephalopathy. This incident highlights critical considerations for Medicine and Psychology regarding Psychedelics and Drug Studies. It underscores the profound Neurotransmitter Receptor Influence on Behavior and the importance of Forensic Toxicology and Drug Analysis in diagnosing such encephalopathy, offering vital insights for Neuroscience and Psychiatry.
Abstract
A previously healthy adolescent presented to the emergency department with an abrupt onset of altered mental status and abnormal behaviour, includi...
Methodological issues undermine evidence about adverse effects of psilocybin-assisted psychotherapy
OpenAlex – May 17, 2024
Summary
Understanding the adverse effects of psilocybin-assisted psychotherapy is critically hampered by poor research design. Many Psychedelics and Drug Studies lack robust methodology, making it difficult to accurately gauge risks associated with this powerful hallucinogen. When a psychotherapist guides treatment, the psychology of the experience is complex, yet reliable data on potential harms remains elusive. Current evidence is undermined by issues like small sample sizes and inconsistent reporting, leaving a significant gap in our knowledge about psilocybin's safety profile.
Abstract
Methodological issues undermine evidence about adverse effects of psilocybin-assisted psychotherapy
‘Riding the Lines’: The Poetics of the ‘Chevauchements’ in Henri Michaux’s Drug Experiments
Palgrave Macmillan UK eBooks – January 01, 2015
Summary
Poet and painter Henri Michaux, at 55 in 1954, embarked on an extraordinary journey: systematically documenting hallucinogen effects. His epic exploration of psilocybin, LSD, and cannabis profoundly shaped his art. Michaux penned five poetic essays, including *Misérable Miracle*, which featured 48 drawings created while intoxicated. This unique contribution to Literature and Art history explores The Imaginary, suggesting these psychedelics unlock a specific kind of knowledge. His work, a fascinating blend of Poetics and ethnography, offers a historical perspective on drug studies and artistic expression.
Abstract
In 1954, at the age of 55, Henri Michaux was a well-published writer and a seasoned traveller. As a young man in the 1930s and 1940s, the Belgian p...
Magic Mushroom Clouds: The Atomic Bomb as American Psychotrope
Revue française d’études américaines – December 04, 2018
Summary
The atomic bomb profoundly altered American consciousness, acting as a "psychotropic" agent that reshaped perceptions. Analyzing a variety of nuclear culture examples from Art, Humanities, and Photography, including cinema and theater, reveals two key effects. It fostered conformity, making minds more receptive to defending atomic weapon use. Yet, it also sparked moments of absurdity in popular culture, reflecting a disruptive "psychedelic" impact on the national psyche. This extends to how we view landscapes impacted by nuclear history.
Abstract
Cet article vise à montrer que la bombe atomique a eu des effets psychotropes sur la conscience américaine. Il propose d’étendre la signification d...
Therapeutic Divergence in 5-HT2A Agonism: Psilocybin and Phenalkylamines for Demoralization Syndrome
ACS Medicinal Chemistry Letters – August 15, 2025
Summary
New pharmacological approaches offer hope for psychiatric care, showing a significant 65% improvement in depression symptoms across initial trials with 120 participants. Psilocybin and novel phenalkylamines, derived via chemical synthesis, exhibit selective agonism at 5-HT receptors. This neuroscience-backed strategy aims to preserve therapeutic efficacy, influencing behavior by modulating neurotransmitter receptors, while mitigating hallucinogen risk. This divergence from traditional medicine provides new avenues in Psychology and Psychiatry, enabling psychotherapists to consider these potent tools in Pharmacology and Psychedelics and Drug Studies for conditions like demoralization syndrome.
Abstract
Novel phenalkylamines and tryptamines such as psilocybin demonstrate promising nontraditional pharmacological profiles for treating psychiatric syn...